Michael Buhle's departure as Chief Executive Officer of Aspira Women's Health Inc. was reported, effective June 17, 2026; the filing names no successor. As of November 6, 2026, Aspira Women's Health Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 30, 2026 to July 7, 2026, naming 2 appointments and 2 departures (Form 8-K, July 7, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Aspira Women's Health Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Michael Buhle · Role: Chief Executive Officer · Effective: 2026-06-17 · 8-K/A, 2026-07-07
- · In / out: Out · Person: Michael Buhle · Role: Chief Executive Officer · 8-K, 2026-06-22
- · In / out: In · Person: John Strahley · Role: Chief Financial Officer and Chief Accounting Officer · Effective: 2026-04-27 · 8-K, 2026-04-30
Aspira Women's Health Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-30 to 2026-07-07. They name 3 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Aspira Women's Health Inc. files it.
Also on the record for Aspira Women's Health Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 22, 2026 | Form D, private offering | $1.49M sold | Form D page | Source |
| June 11, 2026 | Stake report, Schedule 13D/A, by SCHULER JACK W | 8.7% of the class | 5%+ stakes | Source |
| September 19, 2025 | Stake report, Schedule 13D/A, by SCHULER JACK W | 9.1% of the class | 5%+ stakes | Source |
| September 18, 2025 | Form D, private offering | $2.95M sold | Form D page | Source |
| March 20, 2025 | Form D, private offering | $1.37M sold | Form D page | Source |
Selling to them or working with them? See who runs Aspira Women's Health Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aspira Women's Health Inc. and the records around it.
Aspira Women's Health Inc. elsewhere on the record
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
- 5%+ stake filings Jun 2026
- Form D filing Sep 2025
- Who owns it
Companies that share a holder
- SCHULER JACK W also filed stake reports on 1 other company: BIODESIX INC (Jan 2026)
Watch Aspira Women's Health Inc.
Get an email when Aspira Women's Health Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aspira Women's Health Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aspira Women's Health Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aspira Women's Health Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-07 | Out | Chief Executive Officer | 2026-06-17 | 8-K/A, 2026-07-07 | |
| 2026-06-22 | Out | Chief Executive Officer | 8-K, 2026-06-22 | ||
| 2026-06-22 | In | Chief Executive Officer | 2026-06-17 | 8-K, 2026-06-22 | |
| 2026-04-30 | In | Chief Financial Officer and Chief Accounting Officer | 2026-04-27 | 8-K, 2026-04-30 |
Who leads Aspira Women's Health Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Michael Buhle, departure reported (filed 2026-06-22). No successor is named in these filings.
- Chief Financial Officer and Chief Accounting Officer: John Strahley, appointed, effective 2026-04-27 (filed 2026-04-30).
New leaders reset buying decisions — get the Full Report on Aspira Women's Health Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Aspira Women's Health Inc. (free up to 3)
Find people with the same kind of experience as the Chief Executive Officer at Aspira Women's Health Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Aspira Women's Health Inc.Every change, in the filing's words
Departing: Michael Buhle, Chief Executive Officer, effective 2026-06-17
This Amendment No. 1 to Current Report on Form 8-K (this "Amendment") amends the Current Report on Form 8-K filed by Aspira Women's Health Inc. (the "Company") with the Securities and Exchange Commission on June 22, 2026 (the "Original Report"), which reported, among other things, that Michael Buhle ceased serving as the Company's Chief Executive Officer effective June 17, 2026 (the "Separation Date") and that the Board of Directors (the "Board") appointed John (Jack) Fraser as Interim Chief Executive Officer.
- On June 27, 2026, the Company and Mr. Buhle entered into a Separation Agreement and General Release (the "Separation Agreement"), which Mr. Buhle executed on June 28, 2026.
- The Separation Agreement becomes effective on the first calendar day following the expiration of the seven-day revocation period (expected to be on or about July 6, 2026) (the "Effective Date"), subject to Mr. Buhle not revoking the agreement during the seven-day revocation period.
- The material terms of the Separation Agreement are summarized below3 Subject to the Separation Agreement becoming effective, the Company will pay Mr. Buhle cash severance in the aggregate amount of $200,000 (representing six months of base salary), payable in substantially equal installments in accordance with regular payroll practices beginning on the first payroll date following the Effective Date.
- Because Mr. Buhle executed the Separation Agreement on or before June 29, 2026, the Company will pay a prorated amount of $4,615.38 of the severance with its July 15, 2026 payroll run (subject to repayment if Mr. Buhle revokes the Separation Agreement during the revocation period).
Departing: Michael Buhle, Chief Executive Officer
On June 17, 2026, Michael Buhle ceased serving as Chief Executive Officer of Aspira Women's Health Inc. (the "Company").
Appointed: John Fraser, Chief Executive Officer, effective 2026-06-17
Effective June 17, 2026, the board of directors (the "Board") of the Company appointed John Fraser, the Company's current Chairman of the Board, to serve as its Interim Chief Executive Officer while a search of internal and external candidates is conducted.
- Mr. Fraser will also serve as the Company's Principal Executive Officer.
- Mr. Buhle's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- Mr. Fraser, age 66, is the co-founder and co-portfolio manager of Seamark Capital, a fundamentals-based proprietary research growth equities asset management advisor.
- Mr. Fraser holds a B.S. in Business Administration with emphasis in Economics from Bowling Green State University, and an MBA with emphasis in Finance from The Ohio State University.
Appointed: John Strahley, Chief Financial Officer and Chief Accounting Officer, effective 2026-04-27
On April 26, 2026, Aspira Women's Health, Inc. (the "Company") appointed John Strahley as Chief Financial Officer and Chief Accounting Officer of the Company, effective April 27, 2026.
- In connection with Mr. Strahley's appointment, the consulting agreement under which Brian Hungerford had served as Chief Financial Officer terminated effective April 26, 2026.
- Appointment of Principal Financial Officer and Chief Accounting Officer On April 26, 2026, the Company entered into an Executive Employment Agreement (the "Employment Agreement") with John Strahley, pursuant to which Mr. Strahley was appointed as Chief Financial Officer and Chief Accounting Officer of the Company, effective April 27, 2026.
- Mr. Strahley, age 59, brings extensive financial leadership experience to the Company.
- Prior to joining the Company, Mr. Strahley served as CFO of several life science companies, including IsoPlexis Corporation.
- He previously served as a Managing Director at Ironwood Capital and Senior Vice President at Webster Bank.
- He began his career as a Certified Public Accountant.
- The Employment Agreement provides for an annualized base salary of $167,000, payable on a semi-monthly basis.
- Mr. Strahley is not eligible to participate in the Company's group health, dental, vision, or life insurance plans, but is eligible to participate in the Company's 401(k) plan in accordance with its terms.
Aspira Women's Health Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Aspira Women's Health Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.